J&J Says Rybrevant Plus Chemotherapy Delivers Longest Reported Median Overall Survival In EGFR Exon 20 Insertion NSCLC
JNJ•Company brief
Sept. 13 (Reuters) - Johnson & Johnson (JNJ.N):
- J&J - Rybrevant plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion NSCLC
Source text: ID:nPnbt1YV1a
Further company coverage: JNJ.N
